Javascript must be enabled to continue!

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

AbstractExtension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%–98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%–100.0%]) in individuals with different levels of immunosuppression (difference, −2.8% [95% CI, −6.8% to 1.3%]).

Oxford University Press (OUP)

Alexandra Griessbach Frédérique Chammartin Irene A Abela Patrizia Amico Marcel P Stoeckle Anna L Eichenberger Barbara Hasse Dominique L Braun Macé M Schuurmans Thomas F Müller Michael Tamm Annette Audigé Nicolas J Mueller Andri Rauch Huldrych F Günthard Michael T Koller Alexandra Trkola Selina Epp Alain Amstutz Christof M Schönenberger Ala Taji Heravi Katharina Kusejko Heiner C Bucher Matthias Briel Benjamin Speich Irene Abela Karoline Aebi-Popp Alexia Anagnostopoulos Manuel Battegay Enos Bernasconi Dominique Laurent Braun Heiner Bucher Alexandra Calmy Matthias Cavassini Angela Ciuffi Günter Dollenmaier Matthias Egger Luigia Elzi Jan Fehr Jacques Fellay Hansjakob Furrer Christoph Fux Huldrych Günthard Anna Hachfeld David Haerry Barbara Hasse Hans Hirsch Matthias Hoffmann Irene Hösli Michael Huber David Jackson-Perry Christian Kahlert Laurent Kaiser Olivia Keiser Thomas Klimkait Roger Dimitri Kouyos Helen Kovari Katharina Kusejko Niklaus Labhardt Karoline Leuzinger Begona Martinez de Tejada Catia Marzolini Karin J Metzner Nicolas Müller Johannes Nemeth Dunja Nicca Julia Notter Paolo Paioni Giuseppe Pantaleo Matthieu Perreau Andri Rauch Luisa Salazar-Vizcaya Patrick Schmid Roberto Speck Marcel Stöckle Philip Tarr Alexandra Trkola Gilles Wandeler Maja Weisser Sabine Yerly Patrizia Amico John-David Aubert Vanessa Banz Sonja Beckmann Guido Beldi Christoph Berger Ekaterine Berishvili Annalisa Berzigotti Isabelle Binet Pierre-Yves Bochud Sanda Branca Heiner Bucher Emmanuelle Catana Anne Cairoli Yves Chalandon Sabina De Geest Olivier De Rougemont Sophie De Seigneux Michael Dickenmann Joëlle Lynn Dreifuss Michel Duchosal Thomas Fehr Sylvie Ferrari-Lacraz Christian Garzoni Déla Golshayan Nicolas Goossens Fadi Haidar Jörg Halter Dominik Heim Christoph Hess Sven Hillinger Hans H. Hirsch Patricia Hirt Linard Hoessly Günther Hofbauer Uyen Huynh-Do Franz Immer Michael Koller Bettina Laesser Frédéric Lamoth Roger Lehmann Alexander Leichtle Oriol Manuel Hans-Peter Marti Michele Martinelli Valérie McLin Katell Mellac Aurélia Merçay Karin Mettler Nicolas J. Mueller Ulrike Müller-Arndt Beat Müllhaupt Mirjam Nägeli Graziano Oldani Manuel Pascual Jakob Passweg Rosemarie Pazeller Klara Posfay-Barbe Juliane Rick Anne Rosselet Simona Rossi Silvia Rothlin Frank Ruschitzka Thomas Schachtner Stefan Schaub Alexandra Scherrer Aurelia Schnyder Macé Schuurmans Simon Schwab Thierry Sengstag Federico Simonetta Susanne Stampf Jürg Steiger Guido Stirnimann Ueli Stürzinger Christian Van Delden Jean-Pierre Venetz Jean Villard Julien Vionnet Madeleine Wick Markus Wilhelm Patrick Yerly

Open Forum Infectious Diseases

2023

Title: Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Description:

AbstractExtension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.

3% [95% confidence interval {CI}, 91.

9%–98.

7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.

1% [95% CI, 95.

9%–100.

0%]) in individuals with different levels of immunosuppression (difference, −2.

8% [95% CI, −6.

8% to 1.

3%]).

Back

ImportanceThere is a high level of public and professional interest related to potential safety issues of the COVID-19 vaccines; however, no serious adverse cardiovascular events w...

Burden of the Beast

Introduction Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...

The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review

Abstract Introduction Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...

Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)

Abstract Background After basic immunization with 2 mRNA SARS-CoV-2 vaccine doses, only a small proportion of patients who are s...

The Potential of Medicinal Plants and Bioactive Compounds in the Fight Against COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus , is causing a serious worldwide COVID-19 pandemic. The emergence of strains with rapid spread and...

Immune responses to mRNA vaccines : characteristics & the impact of host immune status

<p dir="ltr">mRNA vaccines played a critical role in combating the SARS-CoV-2 pandemic and are progressing toward wider clinical use. However, much of how mRNA vaccines act u...

Immune responses to mRNA vaccines : characteristics & the impact of host immune status

<p dir="ltr">mRNA vaccines played a critical role in combating the SARS-CoV-2 pandemic and are progressing toward wider clinical use. However, much of how mRNA vaccines act u...

Modeling Coronavirus Spike Protein Dynamics: Implications for Immunogenicity and Immune Escape

ABSTRACT The ongoing COVID-19 pandemic is a global public health emergency requiring urgent development of efficacious vaccines. While concentrated research efforts...

Email:
Password:

Email:

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)

Related Results